A Randomized Placebo-Controlled Safety and Pharmacodynamic Study of KB002, an Anti-GM-CSF Monoclonal Antibody, in Patients with Persistent Symptomatic Asthma
Phase of Trial: Phase I/II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs KB 002 (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Humanigen; KaloBios Pharmaceuticals
- 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
- 26 Feb 2013 Results presented at the 69th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History